Maatje D. A. van Gastel

Maatje D. A. van Gastel

Auto-generated profile, based on publicly available information

Maatje D. A. van Gastel

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2018 in JAMA
Verified
Journal Article
Open access
PDF file
EMEsther Meijer
Esther Meijer
FVFolkert W. Visser
Folkert W. Visser
RARene M. M. van Aerts
Rene M. M. van Aerts
CBCharles J. Blijdorp
Charles J. Blijdorp
NCNiek F. Casteleijn
Niek F. Casteleijn
RGRon T. Gansevoort
Ron T. Gansevoort
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys and loss of renal function.1 A 2017 review of epidemiology literature indicated a disease prevalence of approximately 3 to 4 per 10 000.2 End-stage kidney disease, for which dialysis or kidney transplantation is needed, occurs between the fourth and seventh decade of life in the majority of affected patients.1 Registry data collected between 1991 and 2010 showed that approximately 10% of patients receiving kidney replacement therapy had ADPKD.3

3 July 2019 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
MGMaatje D.A. van Gastel
Maatje D.A. van Gastel
MEMarie E. Edwards
Marie E. Edwards
VTVicente E. Torres
Vicente E. Torres
BEBradley J. Erickson
Bradley J. Erickson
RGRon T. Gansevoort
Ron T. Gansevoort
TKTimothy L. Kline
Timothy L. Kline
Significance Statement: Because renal function often remains stable in the early stages of autosomal dominant polycystic kidney disease (ADPKD), total kidney volume (TKV) is the most important biomarker of disease severity and progression. The authors developed and validated a fully automated method of simultaneously measuring TKV and total liver volume (TLV) as well as their growth rates from magnetic resonance images. Their findings indicate that the method’s performance is equivalent to the gold standard of manual tracing while requiring a fraction of the time and skill. This approach may address the unmet need for rapid and reliable assessment of TKV and TLV, allowing identification of patients with rapidly progressing ADPKD for emerging drug treatments and serving as a reliable alternative for assessment of disease progression in clinical trials. Background: The formation and growth of cysts in kidneys, and often liver, in autosomal dominant polycystic kidney disease (ADPKD) cause progressive increases in total kidney volume (TKV) and liver volume (TLV). Laborious and time-consuming manual tracing of kidneys and liver is the current gold standard. We developed a fully automated segmentation method for TKV and TLV measurement that uses a deep learning network optimized to perform semantic segmentation of kidneys and liver. Methods: We used 80% of a set of 440 abdominal magnetic resonance images (T2-weighted HASTE coronal sequences) from patients with ADPKD to train the network and the remaining 20% for validation. Both kidneys and liver were also segmented manually. To evaluate the method’s performance, we used an additional test set of images from 100 patients, 45 of whom were also involved in longitudinal analyses. Results: TKV and TLV measured by the automated approach correlated highly with manually traced TKV and TLV (intraclass correlation coefficients, 0.998 and 0.996, respectively), with low bias and high precision (<0.1%±2.7% for TKV and −1.6%±3.1% for TLV); this was comparable with inter-reader variability of manual tracing (<0.1%±3.5% for TKV and −1.5%±4.8% for TLV). For longitudinal analysis, bias and precision were <0.1%±3.2% for TKV and 1.4%±2.9% for TLV growth. Conclusions: These findings demonstrate a fully automated segmentation method that measures TKV, TLV, and changes in these parameters as accurately as manual tracing. This technique may facilitate future studies in which automated and reproducible TKV and TLV measurements are needed to assess disease severity, disease progression, and treatment response.

1 July 2019 in Kidney International
Verified
Journal Article
Closed access
RGRon T. Gansevoort
Ron T. Gansevoort
MGMaatje D.A. van Gastel
Maatje D.A. van Gastel
ACArlene B. Chapman
Arlene B. Chapman
JBJaime D. Blais
Jaime D. Blais
FCFrank S. Czerwiec
Frank S. Czerwiec
ODOlivier Devuyst
Olivier Devuyst

1 August 2019 in Gastroenterology
Verified
Journal Article
Closed access
RARene M.M. van Aerts
Rene M.M. van Aerts
WKWietske Kievit
Wietske Kievit
HDHedwig M.A. D’aGnolo
Hedwig M.A. D’aGnolo
CBCharles J. Blijdorp
Charles J. Blijdorp
NCNiek F. Casteleijn
Niek F. Casteleijn
JDJoost Drenth
Joost Drenth

13 June 2017 in Annals of Nutrition and Metabolism
Verified
Journal Article
Open access
MGMaatje D.A. van Gastel
Maatje D.A. van Gastel
VTVicente E. Torres
Vicente E. Torres
Vasopressin, also known as arginine vasopressin or antidiuretic hormone, plays a pivotal role in maintaining body homeostasis. Increased vasopressin concentrations, measured by its surrogate copeptin, have been associated with disease severity as well as disease progression in polycystic kidney disease (PKD), and in experimental studies vasopressin has been shown to directly regulate cyst growth. Blocking vasopressin effects on the kidney via the vasopressin V2-receptor and lower circulating vasopressin concentration are potential treatment opportunities that have been the subject of study in PKD in recent years. Treatment with vasopressin V2-receptor antagonist tolvaptan has been shown to inhibit disease progression in experimental studies, as well as in a large randomized controlled trial involving 1,445 patients with autosomal dominant PKD, lowering total kidney volume growth from 5.5 to 2.8%, and the slope of the reciprocal of the serum creatinine level from -3.81 to -2.61 mg per mL-1/year. Alternatively, lowering circulating vasopressin could delay disease progression. Vasopressin is secreted in response to an increased plasma osmolality, which in turn is caused by a low fluid or high osmolar intake. Other lifestyle factors, like smoking, increase vasopressin concentration. Here, we provide a comprehensive review of the physiology as well as pathophysiology of vasopressin in PKD, the promising effects of tolvaptan treatment, and potential synergistic or additive treatments in combination with tolvaptan. In this study, we also review current evidence regarding the effect of influencing disease progression in PKD by lifestyle changes, especially by fluid intake.

1 March 2019 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
BKBart J. Kramers
Bart J. Kramers
MGMaatje D.A. van Gastel
Maatje D.A. van Gastel
WBWendy E. Boertien
Wendy E. Boertien
EMEsther Meijer
Esther Meijer
RGRon T. Gansevoort
Ron T. Gansevoort